✦ LIBER ✦

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

✍ Scribed by Jeffrey R Infante; Leslie A Fecher; Gerald S Falchook; Sujatha Nallapareddy; Michael S Gordon; Carlos Becerra; Douglas J DeMarini; Donna S Cox; Yanmei Xu; Shannon R Morris; Vijay GR Peddareddigari; Ngocdiep T Le; Lowell Hart; Johanna C Bendell; Gail Eckhardt; Razelle Kurzrock; Keith Flaherty; Howard A Burris III; Wells A Messersmith

Book ID: 119608932
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 246 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70270-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity of the oral MEK inhibitor trame

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

✍ Gerald S Falchook; Karl D Lewis; Jeffrey R Infante; Michael S Gordon; Nicholas J 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 225 KB

368 A multi-center Phase 1, dose-escalat

368 A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients

✍ C. Weekes; D.D. Von Hoff; A.A. Adjei; L. Yeh; D. Leffingwell; B. Sheedy; C. Iver 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Phase I, open-label, multicentre, dose-e

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

✍ Patrick Schöffski; Suzanne F. Jones; Herlinde Dumez; Jeffrey R. Infante; Elke Va 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 215 KB

A Phase 1, dose escalation study to eval

A Phase 1, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral daily doses of ELND006 in healthy elderly subjects

✍ Liang, Earvin; Liu, Wenzhong Jerry; Lohr, Lisa; Nguyen, Van; Lin, Holly; Munson, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Navitoclax, a targeted high-affinity inh

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

✍ Wyndham H Wilson; Owen A O'Connor; Myron S Czuczman; Ann S LaCasce; John F Gerec 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 364 KB

A Phase 1 dose-escalation study of the s

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

✍ Shapiro, Geoffrey I.; McCallum, Stewart; Adams, Laurel M.; Sherman, Laurie; Well 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 260 KB